Orthogon Therapeutics, a privately held research and development (R&D) company, uses principles of biophysics and structure-based drug design to develop anti-infective small molecules that ...

Frontiers in Anti-Infective Agents Volume 5 is a collection ... His research work is focused on target-based drug design and synthesis, Methodology development, and development of nanomaterial ...

Infections caused by pathogenic microorganisms, including bacteria, viruses, fungi, and other eukaryotic microbes, seriously ...

This has heightened the company’s core competencies in small-molecule drug design and synthesis and early development, resulting in a rich pipeline. Shionogi’s infectious disease portfolio of ...

AI can predict anti-infective medication activity, drug-target interactions, and therapeutic design. ML approaches to anti-infective drug discovery have centered on training models to identify new ...

A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including ...

It offers different partnering models and is able to design and ... the focus of its anti-infective work. The agreement saw Sanofi transfer 100 employees, more than 10 drug candidates and € ...

The two anti-infective drug candidates should be superior in treating ... is the management team’s proprietary expertise in the design of highly potent compounds with extended lung retention ...

The recent COVID pandemic has served to highlight the importance of developing effective treatments for infection, driving the recent resurgence in anti-infectives drug discovery and development of ...

(AFP) New Delhi: Demand for anti-infective, gastro-intestinal and respiratory drugs grew by double digits in 2024 compared with the previous year at 17.2%, 10.7% and 19.2%, according to the Indian ...